Bortezomib, a first-in-class proteasome inhibitor, has revolutionized the treatment of multiple myeloma and mantle cell lymphoma. Its complex molecular structure necessitates a multi-step synthetic pathway, where the quality and availability of key intermediates are critical for successful production. Among these, N-(2-Pyrazinylcarbonyl)-L-phenylalanine (CAS 114457-94-2) stands out as a crucial building block.

The synthesis of Bortezomib typically begins with chiral amino acids, which are then systematically modified and coupled to form the final drug molecule. N-(2-Pyrazinylcarbonyl)-L-phenylalanine serves as a pre-functionalized amino acid derivative. Its structure incorporates both the L-phenylalanine moiety and the pyrazinylcarbonyl group, which are essential components of the Bortezomib scaffold. The precise stereochemistry of the L-phenylalanine portion is vital, as Bortezomib is a chiral drug, and its biological activity is enantiomer-specific.

As a valued intermediate, sourcing high-purity N-(2-Pyrazinylcarbonyl)-L-phenylalanine is paramount for pharmaceutical manufacturers. This ensures that subsequent synthetic steps proceed efficiently and that the final product meets stringent quality specifications. R&D scientists often look for suppliers that can provide this intermediate with guaranteed purity, typically 98% or higher, and with reliable batch consistency. Access to such materials allows for consistent yields and predictable reaction outcomes.

For procurement specialists, identifying reliable suppliers of N-(2-Pyrazinylcarbonyl)-L-phenylalanine is a strategic imperative. Whether looking to buy for research purposes or for large-scale manufacturing, understanding the role of this intermediate in the Bortezomib synthesis pathway underscores the need for quality assurance. Companies that purchase this compound from reputable manufacturers in China benefit from competitive prices and a secure supply chain.

The continued demand for Bortezomib means that intermediates like N-(2-Pyrazinylcarbonyl)-L-phenylalanine will remain essential. Pharmaceutical companies aiming for efficient production and consistent product quality must prioritize partnerships with suppliers who can deliver this critical intermediate reliably and to exacting standards.